MZL
MCID: MRG003
MIFTS: 52

Marginal Zone B-Cell Lymphoma (MZL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Marginal Zone B-Cell Lymphoma

MalaCards integrated aliases for Marginal Zone B-Cell Lymphoma:

Name: Marginal Zone B-Cell Lymphoma 12 15 37 17 71
Marginal Zone Lymphoma 12 52 58
Mucosa-Associated Lymphoid Tissue Lymphoma 71
Mzl 52

Characteristics:

Orphanet epidemiological data:

58
marginal zone lymphoma
Prevalence: 1-9/100000 (France),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult,elderly;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050748
UMLS via Orphanet 72 C0242647
Orphanet 58 ORPHA300912
UMLS 71 C0242647 C1367654

Summaries for Marginal Zone B-Cell Lymphoma

Disease Ontology : 12 A B-cell lymphoma that is characterized by initial formation in the marginal zones of lymph tissue.

MalaCards based summary : Marginal Zone B-Cell Lymphoma, also known as marginal zone lymphoma, is related to nodal marginal zone b-cell lymphoma and primary cutaneous marginal zone b-cell lymphoma. An important gene associated with Marginal Zone B-Cell Lymphoma is IRF4 (Interferon Regulatory Factor 4), and among its related pathways/superpathways are Innate Immune System and NF-KappaB Family Pathway. The drugs Clarithromycin and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Related Diseases for Marginal Zone B-Cell Lymphoma

Diseases related to Marginal Zone B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 538)
# Related Disease Score Top Affiliating Genes
1 nodal marginal zone b-cell lymphoma 35.4 MALT1 BCL6
2 primary cutaneous marginal zone b-cell lymphoma 35.4 MALT1 IRF4 BCL10
3 splenic marginal zone lymphoma 34.0 MALT1 CD5 BIRC3 BCL6
4 nodal marginal zone lymphoma 33.2 SPN MME KDM4C IRF4 IGHV4-38-2 CD5
5 lymphoma, mucosa-associated lymphoid type 32.7 TNFAIP3 SPN SLC35B2 SIGLEC5 MYD88 MME
6 b-cell lymphoma 32.2 MYD88 MME MIR142 MALT1 IRF4 CD5
7 lymphoma 31.8 MYD88 MME MALT1 IRF4 CD5 CD40LG
8 follicular lymphoma 31.7 MME IRF4 CD5 BCL6 BCL10
9 lymphoma, hodgkin, classic 31.6 KDM4C IRF4 CCR6 BCL6
10 plasmacytoma 31.4 IRF4 CD79A CD5
11 lymphoplasmacytic lymphoma 31.3 MYD88 IRF4 CD5 CD40LG BIRC3
12 mantle cell lymphoma 31.2 SPN MME MALT1 CD5 CD40LG BCL6
13 gastric lymphoma 31.1 MALT1 IRF4 IGHV4-38-2 CD79A BIRC3 BCL6
14 orbit lymphoma 31.1 MALT1 BCL10
15 primary cutaneous diffuse large b-cell lymphoma, leg type 31.1 MYD88 IRF4
16 heavy chain disease 31.0 MYD88 CD79A CD40LG
17 composite lymphoma 31.0 SPN MME IGHV4-38-2 CD79A CD5 BCL6
18 cryoglobulinemia, familial mixed 31.0 CD5 CD40LG
19 thyroid lymphoma 30.9 MME CD5 BCL6
20 monoclonal paraproteinemia 30.9 IGHV4-38-2 CD79A CD40LG
21 lung lymphoma 30.9 SPN MME MALT1 CD79A CD5 BCL6
22 gamma heavy chain disease 30.9 MYD88 IGHV4-38-2 CD40LG
23 mulchandani-bhoj-conlin syndrome 30.9 MME CD40LG CCR6
24 cryoglobulinemia 30.9 CD79A CD5 CD40LG
25 anemia, autoimmune hemolytic 30.9 IGHV4-38-2 CD5 CD40LG CCR6 C1S
26 syphilis 30.9 CD79A CD40LG CCR6
27 central nervous system lymphoma 30.9 MYD88 MALT1 CCR6 BCL6
28 autoimmune lymphoproliferative syndrome, type v 30.8 CD5 BCL6
29 t-cell adult acute lymphocytic leukemia 30.7 IRF4 CD5 CCR6
30 t-cell/histiocyte rich large b cell lymphoma 30.7 MME BCL6
31 waldenstroem's macroglobulinemia 30.6 MYD88 IGHV4-38-2 CD79A CD5 CD40LG
32 evans' syndrome 30.6 MIR142 CD40LG CCR6
33 intestinal disease 30.6 MIR142 KDM4C CCR6 BCL6
34 burkitt lymphoma 30.6 MME IRF4 CD40LG BIRC3 BCL6
35 bladder lymphoma 30.6 SPN MME CD79A CD5 BCL6
36 diffuse large b-cell lymphoma 30.6 TNFAIP3 SPN MYD88 MME MIR142 MALT1
37 toxoplasmosis 30.5 MYD88 CD79A CD40LG
38 richter's syndrome 30.5 SPN IRF4 IGHV4-38-2 CD5
39 secondary syphilis 30.5 CD79A CD40LG
40 gastrointestinal lymphoma 30.5 SPN MME MALT1 CD79A CD5 BCL6
41 connective tissue disease 30.5 MIR223 MIR142 KDM4C CD40LG CCR6
42 breast lymphoma 30.5 SPN MME IRF4 CD79A CD5 BCL6
43 cll/sll 30.4 SPN SLC35B2 MME IGHV4-38-2 CD79A CD5
44 t-cell lymphoblastic leukemia/lymphoma 30.4 TNFAIP3 IRF4 CCR6 BIRC3
45 plasma cell neoplasm 30.4 MME IRF4 IGHV4-38-2 CD79A CD5 CD40LG
46 alpha chain disease 30.3 SPN MALT1 CD79A CD5 CD40LG BIRC3
47 immune deficiency disease 30.3 SPN IRF4 CD79A CD5 CD40LG CCR6
48 myeloma, multiple 29.9 MME MIR142 KDM4C IRF4 IGHV4-38-2 CD79A
49 splenic disease 29.9 SIGLEC5 MYD88 MME IGHV4-38-2 CD5 CD40LG
50 systemic lupus erythematosus 29.9 TNFAIP3 MYD88 MIR223 MIR142 IRF4 CD79A

Graphical network of the top 20 diseases related to Marginal Zone B-Cell Lymphoma:



Diseases related to Marginal Zone B-Cell Lymphoma

Symptoms & Phenotypes for Marginal Zone B-Cell Lymphoma

MGI Mouse Phenotypes related to Marginal Zone B-Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 BCL10 BCL6 BIRC3 CCR6 CD40LG CD5
2 immune system MP:0005387 9.47 BCL10 BCL6 BIRC3 CCR6 CD40LG CD5

Drugs & Therapeutics for Marginal Zone B-Cell Lymphoma

Drugs for Marginal Zone B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clarithromycin Approved Phase 4 81103-11-9 84029
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ofloxacin Approved Phase 4 82419-36-1 4583
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
7
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
8
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
9
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
10
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
11
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
12
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
13 Gastrointestinal Agents Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Antacids Phase 4
16 Anti-Ulcer Agents Phase 4
17 Proton Pump Inhibitors Phase 4
18 Antiprotozoal Agents Phase 4
19 Antiparasitic Agents Phase 4
20 Citrate Phase 4
21 Respiratory System Agents Phase 4
22 diuretics Phase 4
23 Expectorants Phase 4
24
Pixantrone Approved, Investigational Phase 3 144510-96-3
25
Idarubicin Approved Phase 3 58957-92-9 42890
26
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
27
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
28 Orange Approved Phase 3
29
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
30
Chlorambucil Approved Phase 3 305-03-3 2708
31
Dalteparin Approved Phase 3 9005-49-6
32
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
33
Acyclovir Approved Phase 3 59277-89-3 2022
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
35
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
36
Captopril Approved Phase 3 62571-86-2 44093
37
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
38
Ribavirin Approved Phase 3 36791-04-5 37542
39
Palivizumab Approved, Investigational Phase 3 188039-54-5
40
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
41
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
42
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
43
Tazobactam Approved Phase 3 89786-04-9 123630
44
Vancomycin Approved Phase 3 1404-90-6 14969 441141
45
Piperacillin Approved Phase 3 66258-76-2 43672
46
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
47
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
48
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
49
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
50
Ethinyl Estradiol Approved Phase 3 57-63-6 5991

Interventional clinical trials:

(show top 50) (show all 615)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
3 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
4 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
5 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
6 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
7 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
8 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
9 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
10 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
11 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
12 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
13 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
14 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
15 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
16 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
17 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
18 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
19 Treatment of Low-Grade Gastric Non-Hodgkin‘s Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study) Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
20 Randomized Trial of Autologous GVHD for Refractory Lymphoma Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
21 A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
22 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
23 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
24 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
25 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
26 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
27 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
28 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
29 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
30 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
31 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
32 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
33 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
34 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
35 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
36 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
37 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
38 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
39 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
40 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
41 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
42 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
43 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
44 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
45 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
46 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
47 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
48 A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
49 Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) Completed NCT00210353 Phase 3 chlorambucil (drug);rituximab+chlorambucil;rituximab
50 A Phase Ⅲ Clinical Trial for Efficacy, Immunogenicity, Safety and Immune Persistence of Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Aged From 6-15 Years Old. Completed NCT02302170 Phase 3

Search NIH Clinical Center for Marginal Zone B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Marginal Zone B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Marginal Zone B-Cell Lymphoma

Anatomical Context for Marginal Zone B-Cell Lymphoma

MalaCards organs/tissues related to Marginal Zone B-Cell Lymphoma:

40
B Cells, Bone, Bone Marrow, T Cells, Breast, Thyroid, Liver

Publications for Marginal Zone B-Cell Lymphoma

Articles related to Marginal Zone B-Cell Lymphoma:

(show top 50) (show all 2706)
# Title Authors PMID Year
1
Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. 61
32452165 2020
2
Risk of mature B-cell neoplasms and precursor conditions after joint replacement: A report from the Haematological Malignancy Research Network. 61
31675431 2020
3
MALT lymphoma of the colon: a clinicopathological review. 61
32034054 2020
4
Primary cutaneous marginal zone B-cell lymphoma with unusual manifestation and spontaneous regression. 61
32415050 2020
5
Mesenteric lymphadenopathy is a key to diagnosis of radiologically challenging pulmonary lymphoma. 61
32351041 2020
6
TBL1XR1 Mutations in Primary Marginal Zone Lymphomas of Ocular Adnexa are Associated with Unique Morphometric Phenotypes. 61
32339039 2020
7
[Low-grade dural extranodal marginal zone lymphoma]. 61
31948699 2020
8
Marginal zone lymphoma in a dog. 61
32524625 2020
9
Epstein-Barr Virus-negative Marginal Zone Lymphoma as an Uncommon Form of Monomorphic Posttransplant Lymphoproliferative Disorder. 61
32554995 2020
10
Extranodal Marginal Zone Lymphoma of the Central Nervous System Includes Parenchymal-Based Cases With Characteristic Features. 61
32318699 2020
11
Mutational Analysis Reinforces the Diagnosis of Nodal Marginal Zone Lymphoma With Robust PD1-positive T-Cell Hyperplasia. 61
32520760 2020
12
Malignant Lymphoma Mimicking Medial Fat Pad Prolapse: A Pitfall for Upper Eyelid Rejuvenation. 61
32149980 2020
13
BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system. 61
32458259 2020
14
Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas. 61
32249547 2020
15
t(3;14)(p14.1;q32)/FOXP1-IGH translocation in thyroid extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). 61
32534365 2020
16
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. 61
32281275 2020
17
Small Lymphocytic Lymphoma Mimicking Primary Cutaneous Marginal Zone Lymphoma with Colonization of Germinal Center Follicles. 61
32506455 2020
18
Hematologist-Level Classification of Mature B-Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data. 61
32519455 2020
19
Subtype Distribution, Clinical Features, and Survival in B-cell Chronic Lymphoproliferative Disorders in China: A Review of 1592 Cases. 61
32220598 2020
20
Lupus Erythematosus Tumidus Mimicking Primary Cutaneous Marginal Zone B-cell Lymphoma. 61
32556349 2020
21
Leptomeningeal metastasis in a marginal zone lymphoma, presenting as a delirium: case report. 61
32552693 2020
22
Primary dural lymphomas: Clinical presentation, management, and outcome. 61
32176324 2020
23
Subcutaneous marginal zone lymphoma: an unusual lipoma-like presentation. 61
32266425 2020
24
Dural Marginal Zone Lymphoma in a Patient With a Hepatitis C Virus Infection. 61
32494320 2020
25
Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives. 61
32521744 2020
26
Lymphoma of the lacrimal gland - An International Multicenter Retrospective Study. 61
32574779 2020
27
Myeloid Cell Nuclear Differentiation Antigen (MNDA) Positivity in Primary Follicles: Potential Pitfall in the Differential Diagnosis With Marginal Zone Lymphoma. 61
30640752 2020
28
Erratum to "Small cell lymphocytic variant of marginal zone lymphoma: A distinct form of marginal zone lymphoma derived from naïve B cells as a cutaneous counterpart to the naïve marginal zone lymphoma of splenic origin" [Ann. Diagn. Pathol. 34 (2018) 116-121]. 61
32450548 2020
29
Atypical course of an infective endocarditis in a patient with complex congenital heart disease, chronic hepatitis B and splenic marginal zone lymphoma. 61
32426956 2020
30
Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma. 61
32223334 2020
31
Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma: A Potential Diagnostic Pitfall. 61
31764221 2020
32
Flow cytometric features of incidental indolent T lymphoblastic proliferations. 61
31571375 2020
33
Endocytoscopy for the diagnosis of marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type in the rectum: Report of two cases. 61
31782221 2020
34
The Diagnostic Utility of Splenectomy in Idiopathic Splenomegaly. 61
32394013 2020
35
Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. 61
32108027 2020
36
Orbital marginal cell lymphoma and mantle cell lymphoma subclone in patient with monoclonal gammopathy of unknown significance. 61
32363993 2020
37
Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies. 61
32481736 2020
38
Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the lacrimal drainage system in two pediatric patients. 61
30862184 2020
39
Population-based study of patients with primary Sjögren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. 61
32153241 2020
40
Splenic Marginal Zone Lymphoma in Turkey: Association with Hepatitis B Instead of Hepatitis C Virus as an Etiologic and Possible Prognostic Factor - A Multicenter Cohort Study 61
31630512 2020
41
Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis. 61
32452658 2020
42
Alteration of Cell Surface Markers CD38 and CD138 in Lymphoproliferative Disorders in the Ocular Adnexa. 61
32234892 2020
43
Primary cutaneous marginal zone lymphoma treated with doxycycline in a pediatric patient. 61
32323885 2020
44
Extranodal marginal zone lymphoma: an unusual cause of gastric subepithelial tumor. 61
32306714 2020
45
PET/CT in Disease Detection and Follow-up of Subcutaneous Involvement in Marginal Zone Lymphoma. 61
32115401 2020
46
Pediatric Lymphoma and Solid Tumors Associated With Cancer Susceptibility Syndromes. 61
32282651 2020
47
Ultrasound-guided biopsy of suspected salivary gland lymphoma in Sjögren's syndrome. 61
32248649 2020
48
90 Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study. 61
31944265 2020
49
Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) outside of clinical trials: Real-world data from the University of Vienna. 61
32347560 2020
50
Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma. 61
31931656 2020

Variations for Marginal Zone B-Cell Lymphoma

Expression for Marginal Zone B-Cell Lymphoma

Search GEO for disease gene expression data for Marginal Zone B-Cell Lymphoma.

Pathways for Marginal Zone B-Cell Lymphoma

GO Terms for Marginal Zone B-Cell Lymphoma

Cellular components related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.56 MME CD79A BIRC3 BCL10
2 external side of plasma membrane GO:0009897 9.55 IGHV4-38-2 CD79A CD5 CD40LG CCR6
3 CBM complex GO:0032449 8.96 MALT1 BCL10
4 polkadots GO:0002096 8.62 MALT1 BCL10

Biological processes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.95 MYD88 IRF4 CD79A C1S BCL6 BCL10
2 negative regulation of apoptotic process GO:0043066 9.93 MYD88 MALT1 CD40LG BIRC3 BCL6
3 regulation of apoptotic process GO:0042981 9.85 MALT1 BIRC3 BCL6 BCL10
4 defense response to bacterium GO:0042742 9.83 SPN MYD88 MIR223 IGHV4-38-2
5 cellular response to lipopolysaccharide GO:0071222 9.76 TNFAIP3 MYD88 MALT1 BCL10
6 regulation of inflammatory response GO:0050727 9.73 MYD88 BIRC3 BCL6
7 B cell differentiation GO:0030183 9.69 CD79A CD40LG BCL6
8 positive regulation of protein ubiquitination GO:0031398 9.67 MALT1 BIRC3 BCL10
9 immunoglobulin mediated immune response GO:0016064 9.57 MYD88 BCL10
10 cellular defense response GO:0006968 9.5 SPN CCR6 BCL10
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.46 MYD88 MALT1 CD40LG BCL10
12 regulation of T cell migration GO:2000404 9.43 SPN CCR6
13 regulation of T cell receptor signaling pathway GO:0050856 9.4 MALT1 BCL10
14 response to fungus GO:0009620 9.37 MALT1 BCL10
15 regulation of germinal center formation GO:0002634 9.26 TNFAIP3 BCL6
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.13 MYD88 MALT1 BCL10
17 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.02 SLC35B2 MYD88 MALT1 BIRC3 BCL10

Molecular functions related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 TNFAIP3 MYD88 MALT1 CD79A C1S BCL6
2 kinase activator activity GO:0019209 8.96 MALT1 BCL10
3 protein self-association GO:0043621 8.92 TNFAIP3 MYD88 MALT1 BCL10

Sources for Marginal Zone B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....